StreetInsider.com News Articles

Exelixis to Release Third Quarter 2026 Financial Results on Thursday, October 29, 2026

Thu, 15 Oct 2026 16:05:00 -0400

– Conference Call and Webcast to Follow at 5:00 p.m. ET / 2:00 p.m. PT –

ALAMEDA, Calif.--(BUSINESS WIRE)-- Exelixis, Inc. (Nasdaq: EXEL) announced today that its third quarter 2026 financial results will be released on Thursday, October 29, 2026, after the markets close. At 5:00 p.m. ET / 2:00 p.m. PT, Exelixis management will host a conference call and webcast to discuss the results and provide a general business update. Access to the event will be available via the Internet from the company’s website.

To access the conference call, please register using this

Exelixis to Release Third Quarter 2026 Financial Results on Thursday, October 29, 2026

Thu, 15 Oct 2026 16:05:00 -0400

– Conference Call and Webcast to Follow at 5:00 p.m. ET / 2:00 p.m. PT –

To access the conference call, please register using this

Exelixis (EXEL) PT Lowered to $45 at RBC Capital

Thu, 08 Oct 2026 08:27:18 -0400

RBC Capital analyst Leonid Timashev lowered the price target on Exelixis (NASDAQ: EXEL) to $45.00 (from $46.00) while maintaining a Sector Perform rating.

Exelixis (EXEL) PT Raised to $54 at Truist Securities

Wed, 07 Oct 2026 07:13:28 -0400

Truist Securities analyst Gregory Renza raised the price target on Exelixis (NASDAQ: EXEL) to $54.00 (from $52.00) while maintaining a Hold rating.

Leerink Assumes Exelixis (EXEL) at Market Perform

Mon, 05 Oct 2026 06:24:25 -0400

Leerink analyst Asthika Goonewardene assumes coverage on Exelixis (NASDAQ: EXEL) with a Market Perform rating and a price target of $55.00.

For an analyst ratings summary and ratings history on Exelixis click here. For more ratings news on Exelixis click here.

Shares of Exelixis closed at $58.39 yesterday.

Citizens Reiterates Market Outperform Rating on Exelixis (EXEL)

Mon, 14 Sep 2026 09:40:48 -0400

Citizens analyst Silvan Turkcan reiterated a Market Outperform rating and $55.00 price target on Exelixis (NASDAQ: EXEL).

The analyst commented, "Exelixis announced that the FDA has extended the review period for zanzalintinib's NDA for mCRC following a major amendment due to updated safety and efficacy data. The PDUFA target action date has been extended to March 3, 2027 from December 3, 2026. In our view, these events are likely based on FDA procedure and are not indicative of a significant application issue, see details below. We maintain our Market Outperform rating and $55 DCF-derived price target."

For an analyst ratings summary and

FDA extends Exelixis zanzalintinib review by three months

Fri, 11 Sep 2026 07:05:05 -0400

Exelixis, Inc. (NASDAQ: EXEL) announced that the U.S. Food and Drug Administration has extended the review period for its new drug application for zanzalintinib, in combination with atezolizumab, for the treatment of metastatic colorectal cancer by three months.

The FDA notified Exelixis of the extension on September 10, 2026. The agency classified the extension as a major amendment, prompted by updated safety and efficacy data that Exelixis submitted in response to an FDA information request.

The updated Prescription Drug User Fee Act action date is now March 3, 2027.

FDA extends Exelixis zanzalintinib review by three months

Fri, 11 Sep 2026 07:05:05 -0400

The updated Prescription Drug User Fee Act action date is now March 3, 2027.

FDA extends Exelixis zanzalintinib review by three months

Fri, 11 Sep 2026 07:05:05 -0400

The updated Prescription Drug User Fee Act action date is now March 3, 2027.

Form 8-K EXELIXIS, INC. For: Sep 10

Fri, 11 Sep 2026 07:00:00 -0400

si-local-file:///var/storage/secattach/20260911/27050652.html

BMO Capital Starts Exelixis (EXEL) at Market Perform

Wed, 19 Aug 2026 05:31:44 -0400

(Updated - August 19, 2026 5:31 AM EDT)

BMO Capital analyst David Lebowitz initiates coverage on Exelixis (NASDAQ: EXEL) with a Market Perform rating, PT $54.00.

The analyst comments "We initiate coverage of Exelixis (EXEL) with a Market Perform rating and a $54 target price. Exelixis is a commercial-stage oncology company anchored by cabozantinib, which generated ~$2.12 billion in FY25. The franchise is durable, high margin, and cash generative. However, the drug is proceeding toward a patent cliff in early 2030. While follow-up drug zanzalintinib offers a potentially promising bridge forward, it is not fully de-risked and its future stream does not

BMO Capital Starts Exelixis (EXEL) at Market Perform

Wed, 19 Aug 2026 05:31:44 -0400

(Updated - August 19, 2026 5:31 AM EDT)

BMO Capital analyst David Lebowitz initiates coverage on Exelixis (NASDAQ: EXEL) with a Market Perform rating, PT $54.00.

Form SCHEDULE 13D/A EXELIXIS, INC. Filed by: FARALLON CAPITAL MANAGEMENT, L.L.C.

Fri, 14 Aug 2026 08:21:00 -0400

si-local-file:///var/storage/secattach/20260814/26925018.html

Form SCHEDULE 13D/A EXELIXIS, INC. Filed by: FARALLON CAPITAL MANAGEMENT, L.L.C.

Fri, 14 Aug 2026 08:21:00 -0400

si-local-file:///var/storage/secattach/20260814/26925018.html

Form 4 EXELIXIS, INC. For: Aug 10 Filed by: Beckerle Mary C

Wed, 12 Aug 2026 19:34:00 -0400

si-local-file:///var/storage/secattach/20260812/26914809.html

Form 4 EXELIXIS, INC. For: Aug 10 Filed by: Beckerle Mary C

Wed, 12 Aug 2026 19:34:00 -0400

si-local-file:///var/storage/secattach/20260812/26914809.html

Form SCHEDULE 13G/A EXELIXIS, INC. Filed by: AQR CAPITAL MANAGEMENT LLC

Wed, 12 Aug 2026 07:18:00 -0400

si-local-file:///var/storage/secattach/20260812/26908874.html

Form SCHEDULE 13G/A EXELIXIS, INC. Filed by: AQR CAPITAL MANAGEMENT LLC

Wed, 12 Aug 2026 07:18:00 -0400

si-local-file:///var/storage/secattach/20260812/26908874.html

Form 144 EXELIXIS, INC. Filed by: Beckerle Mary C

Mon, 10 Aug 2026 16:15:00 -0400

si-local-file:///var/storage/secattach/20260810/26898115.html

Form 144 EXELIXIS, INC. Filed by: Beckerle Mary C

Mon, 10 Aug 2026 16:15:00 -0400

si-local-file:///var/storage/secattach/20260810/26898115.html

Leerink Downgrades Exelixis (EXEL) to Market Perform

Thu, 06 Aug 2026 13:39:00 -0400

Leerink analyst Christopher Liu downgraded Exelixis (NASDAQ: EXEL) from Outperform to Market Perform, PT $52.00.

For an analyst ratings summary and ratings history on Exelixis click here. For more ratings news on Exelixis click here.

Shares of Exelixis closed at $56.70 yesterday.

Exelixis (EXEL) PT Raised to $51 at Stifel

Thu, 06 Aug 2026 08:09:27 -0400

Stifel analyst Stephen Willey raised the price target on Exelixis (NASDAQ: EXEL) to $51.00 (from $47.00) while maintaining a Hold rating.

Exelixis (EXEL) PT Lowered to $52 at Truist Securities

Thu, 06 Aug 2026 07:22:20 -0400

Truist Securities analyst Gregory Renza lowered the price target on Exelixis (NASDAQ: EXEL) to $52.00 (from $56.00) while maintaining a Hold rating.

Exelixis (EXEL) PT Raised to $50 at Wells Fargo

Thu, 06 Aug 2026 06:38:46 -0400

Wells Fargo analyst Eva Fortea Verdejo raised the price target on Exelixis (NASDAQ: EXEL) to $50.00 (from $49.00) while maintaining a Equal Weight rating.

Form S-8 EXELIXIS, INC.

Wed, 05 Aug 2026 16:26:00 -0400

si-local-file:///var/storage/secattach/20260805/26874908.html